2016
DOI: 10.21115/jbes.v8.n1.p24-38
|View full text |Cite
|
Sign up to set email alerts
|

Sequenciamento de biológicos em câncer colorretal metastático (CCRm): uma análise de comparação de custos para pacientes CCRm RAS selvagens no Brasil

Abstract: Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil ABSTRACTObjective: To compare the treatment costs of different sequences of regimens including monoclonal antibodies in metastatic colorectal cancer (CRCm) treatment for the Brazilian Supplementary Healthcare System. Methods: Sixteen scenarios were analyzed, each one comparing a sequence of bevacizumab TML plus an anti-EGFR therapy in the third-line with another sequence w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…Adequate information about the molecular status of mCRC patients has an impact on the clinical decision-making process for oncologists, as appointed by a nation-wide survey conducted by the Brazilian Group of Gastrointestinal Tumors [33]. In addition, the knowledge generated by our study could help health care authorities to develop a more efficient administration of resources in Brazil, as demonstrated in a cost-comparison analysis of sequential therapies in the Brazilian population [34].…”
Section: Discussionmentioning
confidence: 84%
“…Adequate information about the molecular status of mCRC patients has an impact on the clinical decision-making process for oncologists, as appointed by a nation-wide survey conducted by the Brazilian Group of Gastrointestinal Tumors [33]. In addition, the knowledge generated by our study could help health care authorities to develop a more efficient administration of resources in Brazil, as demonstrated in a cost-comparison analysis of sequential therapies in the Brazilian population [34].…”
Section: Discussionmentioning
confidence: 84%